Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Botanix Pharmaceuticals Limited ( (AU:BOT) ) has issued an update.
Botanix Pharmaceuticals has updated investors on its plans for a new issue of securities under a share purchase plan, conducted via a prospectus and structured as a non-pro rata offer. The company is seeking quotation of the new securities on the ASX, in line with its strategy of using equity markets to fund ongoing operations and growth initiatives.
The revised timetable sets the SPP offer period from 11 March to 13 April 2026, with a shareholder meeting on 1 April to approve the issuance. Subject to that approval, the new securities are scheduled to be issued on 20 April 2026, clarifying the capital-raising timeline for existing shareholders and potential participants in the offer.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$1.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
More about Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Ltd is an ASX-listed pharmaceutical company focused on developing and commercialising dermatology and other therapeutic products. The company operates in the biotech and life sciences sector, raising capital through public markets to support its product development and corporate activities.
Average Trading Volume: 9,220,497
Technical Sentiment Signal: Sell
Current Market Cap: A$119.8M
Find detailed analytics on BOT stock on TipRanks’ Stock Analysis page.